Inflammatory breast cancer

What we know and what we need to learn

Hideko Yamauchi, Wendy A. Woodward, Vicente Valero, Ricardo H. Alvarez, Anthony Lucci, Thomas A. Buchholz, Takayuki Iwamoto, Savitri Krishnamurthy, Wei Yang, James M. Reuben, Gabriel N. Hortobágyi, Naoto T. Ueno

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Purpose. We review the current status of multidisciplinary care for patients with inflammatory breast cancer (IBC) and discuss what further research is needed to advance the care of patients with this disease. Design. We performed a comprehensive review of the English-language literature on IBC through computerized literature searches. Results. Significant advances in imaging, including digital mammography, high-resolution ultrasonography with Doppler capabilities, magnetic resonance imaging, and positron emission omography-computed tomography, have improved the diagnosis and staging of IBC. There are currently no established molecular criteria for distinguishing IBC from noninflammatory breast cancer. Such criteria would be helpful for the diagnosis and development of novel targeted therapies. Combinations of neoadjuvant systemic chemotherapy, surgery, and radiation therapy have led to an improved prognosis; however, the overall 5-year survival rate for patients with IBC remains very low (~30%). Sentinel lymph node biopsy and skin-sparing mastectomy are not recommended for patients with IBC. Conclusion. Optimal management of IBC requires close coordination among medical, surgical, and radiation oncologists, as well as radiologists and pathologists. There is a need to identify molecular changes that define the pathogenesis of IBC to enable eradication of IBC with the use of IBC-specific targeted therapies.

Original languageEnglish
Pages (from-to)891-899
Number of pages9
JournalOncologist
Volume17
Issue number7
DOIs
Publication statusPublished - Jul 2012
Externally publishedYes

Fingerprint

Inflammatory Breast Neoplasms
Patient Care
Emission-Computed Tomography
Breast Neoplasms
Sentinel Lymph Node Biopsy
Doppler Ultrasonography
Mastectomy
Mammography
Language
Radiotherapy
Survival Rate
Magnetic Resonance Imaging

Keywords

  • Inflammatory breast cancer
  • Systemic therapy
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Yamauchi, H., Woodward, W. A., Valero, V., Alvarez, R. H., Lucci, A., Buchholz, T. A., ... Ueno, N. T. (2012). Inflammatory breast cancer: What we know and what we need to learn. Oncologist, 17(7), 891-899. https://doi.org/10.1634/theoncologist.2012-0039

Inflammatory breast cancer : What we know and what we need to learn. / Yamauchi, Hideko; Woodward, Wendy A.; Valero, Vicente; Alvarez, Ricardo H.; Lucci, Anthony; Buchholz, Thomas A.; Iwamoto, Takayuki; Krishnamurthy, Savitri; Yang, Wei; Reuben, James M.; Hortobágyi, Gabriel N.; Ueno, Naoto T.

In: Oncologist, Vol. 17, No. 7, 07.2012, p. 891-899.

Research output: Contribution to journalArticle

Yamauchi, H, Woodward, WA, Valero, V, Alvarez, RH, Lucci, A, Buchholz, TA, Iwamoto, T, Krishnamurthy, S, Yang, W, Reuben, JM, Hortobágyi, GN & Ueno, NT 2012, 'Inflammatory breast cancer: What we know and what we need to learn', Oncologist, vol. 17, no. 7, pp. 891-899. https://doi.org/10.1634/theoncologist.2012-0039
Yamauchi H, Woodward WA, Valero V, Alvarez RH, Lucci A, Buchholz TA et al. Inflammatory breast cancer: What we know and what we need to learn. Oncologist. 2012 Jul;17(7):891-899. https://doi.org/10.1634/theoncologist.2012-0039
Yamauchi, Hideko ; Woodward, Wendy A. ; Valero, Vicente ; Alvarez, Ricardo H. ; Lucci, Anthony ; Buchholz, Thomas A. ; Iwamoto, Takayuki ; Krishnamurthy, Savitri ; Yang, Wei ; Reuben, James M. ; Hortobágyi, Gabriel N. ; Ueno, Naoto T. / Inflammatory breast cancer : What we know and what we need to learn. In: Oncologist. 2012 ; Vol. 17, No. 7. pp. 891-899.
@article{b478a700ad2d4d7ea28ec483ba72f479,
title = "Inflammatory breast cancer: What we know and what we need to learn",
abstract = "Purpose. We review the current status of multidisciplinary care for patients with inflammatory breast cancer (IBC) and discuss what further research is needed to advance the care of patients with this disease. Design. We performed a comprehensive review of the English-language literature on IBC through computerized literature searches. Results. Significant advances in imaging, including digital mammography, high-resolution ultrasonography with Doppler capabilities, magnetic resonance imaging, and positron emission omography-computed tomography, have improved the diagnosis and staging of IBC. There are currently no established molecular criteria for distinguishing IBC from noninflammatory breast cancer. Such criteria would be helpful for the diagnosis and development of novel targeted therapies. Combinations of neoadjuvant systemic chemotherapy, surgery, and radiation therapy have led to an improved prognosis; however, the overall 5-year survival rate for patients with IBC remains very low (~30{\%}). Sentinel lymph node biopsy and skin-sparing mastectomy are not recommended for patients with IBC. Conclusion. Optimal management of IBC requires close coordination among medical, surgical, and radiation oncologists, as well as radiologists and pathologists. There is a need to identify molecular changes that define the pathogenesis of IBC to enable eradication of IBC with the use of IBC-specific targeted therapies.",
keywords = "Inflammatory breast cancer, Systemic therapy, Targeted therapy",
author = "Hideko Yamauchi and Woodward, {Wendy A.} and Vicente Valero and Alvarez, {Ricardo H.} and Anthony Lucci and Buchholz, {Thomas A.} and Takayuki Iwamoto and Savitri Krishnamurthy and Wei Yang and Reuben, {James M.} and Hortob{\'a}gyi, {Gabriel N.} and Ueno, {Naoto T.}",
year = "2012",
month = "7",
doi = "10.1634/theoncologist.2012-0039",
language = "English",
volume = "17",
pages = "891--899",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "7",

}

TY - JOUR

T1 - Inflammatory breast cancer

T2 - What we know and what we need to learn

AU - Yamauchi, Hideko

AU - Woodward, Wendy A.

AU - Valero, Vicente

AU - Alvarez, Ricardo H.

AU - Lucci, Anthony

AU - Buchholz, Thomas A.

AU - Iwamoto, Takayuki

AU - Krishnamurthy, Savitri

AU - Yang, Wei

AU - Reuben, James M.

AU - Hortobágyi, Gabriel N.

AU - Ueno, Naoto T.

PY - 2012/7

Y1 - 2012/7

N2 - Purpose. We review the current status of multidisciplinary care for patients with inflammatory breast cancer (IBC) and discuss what further research is needed to advance the care of patients with this disease. Design. We performed a comprehensive review of the English-language literature on IBC through computerized literature searches. Results. Significant advances in imaging, including digital mammography, high-resolution ultrasonography with Doppler capabilities, magnetic resonance imaging, and positron emission omography-computed tomography, have improved the diagnosis and staging of IBC. There are currently no established molecular criteria for distinguishing IBC from noninflammatory breast cancer. Such criteria would be helpful for the diagnosis and development of novel targeted therapies. Combinations of neoadjuvant systemic chemotherapy, surgery, and radiation therapy have led to an improved prognosis; however, the overall 5-year survival rate for patients with IBC remains very low (~30%). Sentinel lymph node biopsy and skin-sparing mastectomy are not recommended for patients with IBC. Conclusion. Optimal management of IBC requires close coordination among medical, surgical, and radiation oncologists, as well as radiologists and pathologists. There is a need to identify molecular changes that define the pathogenesis of IBC to enable eradication of IBC with the use of IBC-specific targeted therapies.

AB - Purpose. We review the current status of multidisciplinary care for patients with inflammatory breast cancer (IBC) and discuss what further research is needed to advance the care of patients with this disease. Design. We performed a comprehensive review of the English-language literature on IBC through computerized literature searches. Results. Significant advances in imaging, including digital mammography, high-resolution ultrasonography with Doppler capabilities, magnetic resonance imaging, and positron emission omography-computed tomography, have improved the diagnosis and staging of IBC. There are currently no established molecular criteria for distinguishing IBC from noninflammatory breast cancer. Such criteria would be helpful for the diagnosis and development of novel targeted therapies. Combinations of neoadjuvant systemic chemotherapy, surgery, and radiation therapy have led to an improved prognosis; however, the overall 5-year survival rate for patients with IBC remains very low (~30%). Sentinel lymph node biopsy and skin-sparing mastectomy are not recommended for patients with IBC. Conclusion. Optimal management of IBC requires close coordination among medical, surgical, and radiation oncologists, as well as radiologists and pathologists. There is a need to identify molecular changes that define the pathogenesis of IBC to enable eradication of IBC with the use of IBC-specific targeted therapies.

KW - Inflammatory breast cancer

KW - Systemic therapy

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84864129824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864129824&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2012-0039

DO - 10.1634/theoncologist.2012-0039

M3 - Article

VL - 17

SP - 891

EP - 899

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 7

ER -